Date: 2013-07-29
Type of information: Licensing agreement
Compound: monoclonal antibody targeting the Her3 receptor tyrosine kinase
Company: MedImmune (USA - global biologics arm of AstraZeneca (UK) Kolltan (USA)
Therapeutic area: undisclosed
Type agreement: licensing
Action mechanism:
Disease:
Details: * On July 29, 2013, Kolltan Pharmaceuticals, a privately held biopharmaceutical company, has announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, under which Kolltan will in-license a monoclonal antibody targeting the Her3 receptor tyrosine kinase from MedImmune. Based on the current program status, Kolltan anticipates initiating Phase 1 clinical testing of this product in the first quarter of 2014. As part of the agreement, both companies will have the potential for future cost-, risk- and profit-sharing for this product candidate after Kolltan completes early clinical testing. Financial details of the agreement were not disclosed.
Financial terms:
Latest news:
